CO Rebinding to Protoheme
A R T I C L E S
and exit channels, as well as docking sites and cavities within
the protein, lead to a complexity in the overall reaction process
that is still not fully understood.1
mediated intermediate states and the distal pocket contribution,
is to study the CO rebinding kinetics of heme model compounds
with and without the proximal imidazole ligand. Surprisingly,
a complete set of such kinetic measurements has not been
reported and analyzed. If Fe-PPIX is simply dissolved in
aqueous solution at high pH, then dimerization takes place,
2-14,24-30
The specific interactions that control the activation barrier
for the Fe-diatomic bond formation in terms of the heme, the
proximal ligand, and the distal pocket protein architecture have
been studied extensively. For simplicity, the enthalpic part of
the ligand rebinding barrier can be separated into two contribu-
tions: the proximal term, HP, which is controlled by the
proximal ligand and the heme geometry (e.g., the Fe out-of-
plane displacement) and the distal term, HD, which is determined
by the distal pocket environment around the dissociated ligand.
It remains unclear if one or the other of these two terms
dominates the overall enthalpic barrier, or if both are equally
39
which significantly perturbs the rebinding kinetics. To prevent
heme dimerization, it is possible to use micelles formed from
materials such as CTAB (cetyltrimethylammonium bromide),
which stabilize the hemes in a monodispersed solution.4
Model compound kinetic studies have been performed in
CTAB under conditions where an imidazole ligand is bound to
0,41
1
8,23
the heme.
However, for such compounds, the CO ligand
escape rate is much larger than its geminate rebinding rate, so
the latter process is difficult or impossible to detect.23 Moreover,
in the absence of an added imidazole ligand, the CTAB
encapsulated heme samples again display complex kinetic
evolution, probably due to a base elimination mechanism1
(i.e., upon CO photolysis, there is a delayed dissociation of the
weak proximal base before CO rebinds). The problems men-
tioned above have made clear kinetic comparisons between the
imidazole ligated and unligated species problematic.
important, as suggested by a prior analysis of the nonexponential
rebinding kinetics of MbCO at low temperatures.3
1,32
On the
other hand, when the entropic part of the free energy rebinding
barrier is considered, the distal contribution (associated with
the ligand accessible volumes33 of the distal pocket and the Xe4
cavity) is more important than the proximal contribution.
Several studies of Mb under conditions (e.g., low pH, H93G
mutation) that remove the proximal histidine (His93) ligand have
been carried out in order to determine its contribution to the
8,42
In contrast to FePPIX-CO kinetics in CTAB solutions, early
10,15,34,35
16,17,43-45
rebinding barrier.
Unfortunately, the situation becomes
studies
of CO binding to iron PPIX in highly concen-
complex because of the increased acidity of the iron atom when
CO binds. For example, the complex ligation kinetics observed
for Mb at low pH required a ligand switching model involving
both His93 and H2O as possible ligands.3 The ligand switch
arises because of the presence of the Fe-His bond when CO is
trated glycerol solutions (with no added proximal ligand)
revealed a relatively simple kinetic response, suggesting that
heme aggregation and spurious proximal ligation was not a
problem under these highly viscous solution conditions. Kinetic
measurements of diatomic ligand binding to FePPIX in the
presence of a proximal imidazole ligand are also feasible under
identical conditions of highly concentrated glycerol. For ex-
ample, Traylor and Magde used 1-methlyimidazole (1-MeIm)
as a ligand to form a 1-MeImFePPIX-CO complex in 98%
glycerol and observed a geminate yield of 0.4 with a ∼300 ps
time constant. However, there have been no systematic attempts
made to isolate and assess the effects of proximal imidazole
ligation on the CO geminate rebinding kinetics using a self-
consistent set of solution conditions.
5
bound to the partially unfolded3 protein at low pH. In contrast,
5,36
a transient proximal Fe-OH2 bond is formed3
5,36
when CO is
19
photolyzed. In the case of the H93G mutant of Mb, where the
native proximal His93 ligand is replaced by glycine and no
exogenous ligand is added, another histidine (His97) is recruited
as the proximal ligand when CO binds and acidifies the heme
3
7,38
iron.
As a result of these complexities, the kinetic effects
of removing the proximal histidine ligand have not been isolated
in Mb using either pH induced unfolding or the H93G mutant
system.
One obvious way to probe the proximal contribution to the
rebinding barrier, free of complications from the various protein-
The measurements reported here present the first such
controlled comparisons of the CO geminate rebinding kinetics,
with and without a proximal imidazole ligand. We study heme
in its bare form, FePPIX, without the protein matrix and we
focus on the effect of the proximal ligand by adding exogenous
(
25) Lim, M.; Jackson, T. A.; Anfinrud, P. A. Nat. Struct. Biol. 1997, 4, 209-
14.
2
2-methylimidazole (2-MeIm) to the heme in highly concentrated
(
26) Brunori, M.; Vallone, B.; Cutruzzol a` , F.; Travaglini-Allocatelli, C.;
Berendzen, J.; Chu, K.; Sweet, R. M.; Schlichting, I. Proc. Natl. Acad.
Sci. U.S.A. 2000, 97, 2058-2063.
(80-95%) glycerol solution. We quantitatively compare the
kinetics of the imidazole ligated species to that of the unligated
bare heme in the same highly viscous glycerol solution, where
(
27) Tian, W. D.; Sage, J. T.; Champion, P. M.; Chien, E.; Sligar, S. G.
Biochemistry 1996, 35, 3487-3502.
(
(
28) Elber, R.; Karplus, M. J. Am. Chem. Soc. 1990, 112, 9161-9175.
29) Cao, W.; Christian, J. F.; Champion, P. M.; Rosca, F.; Sage, J. T.
Biochemistry 2001, 40, 5728-5737.
it is known to undergo very rapid and large amplitude CO
20,44
geminate recombination.
Such measurements directly probe
(
30) Schotte, F.; Lim, M.; Jackson, T. A.; Smirnov, A. V.; Soman, J.; Olson, J.
Hp, the contribution of the proximal imidazole ligation to the
CO rebinding barrier. In addition, we are also able to compare
S.; Phillips, G. N., Jr.; Wulff, M.; Anfinrud, P. A. Science 2003, 300, 1944-
1
947.
(
(
31) Srajer, V.; Champion, P. M. Biochemistry 1991, 30, 7390-7402.
32) Srajer, V.; Reinisch, L.; Champion, P. M. J. Am. Chem. Soc. 1988, 110,
6
656-6670.
(39) White, W. I. In The Porphyrins; Dolphin, D., Ed. Academic: NewYork:
1979.
(40) Simplicio, J.; Schwenzer, K. Biochemistry 1973, 12, 1923-1929.
(41) Medhi, O. K.; Mazumdar, S.; Mitra, S. Inorg. Chem. 1989, 28, 3243-
3248.
(42) Larsen, R. W. Inorg. Chim. Acta 1999, 288, 74-81.
(43) Beece, D.; Eisenstein, L.; Frauenfelder, H.; Good, D.; Marden, M. C.;
Reinisch, L.; Reynolds, A. H.; Sorensen, L. B.; Yue, K. T. Biochemistry
1980, 19, 5147-5157.
(44) Miers, J. B.; Postlewaite, J. C.; Zyung, T.; Chen, S.; Roemig, G. R.; Wen,
X.; Dlott, D. D.; Szabo, A. J. Chem. Phys. 1990, 93, 8771-8776.
(45) Moore, J. N.; Hansen, P. A.; Hochstrasser, R. M. Proc. Natl. Acad. Sci.
U.S.A. 1988, 85, 5062-5066.
(
(
(
(
(
(
33) Tilton, R. F., Jr.; Kuntz, I. D. Jr.; Petsko, G. A. Biochemistry 1984, 23,
849-2857.
34) Decatur, S. M.; DePillis, G. D.; Boxer, S. G. Biochemistry 1996, 35, 3925-
932.
35) Sage, J. T.; Morikis, D.; Champion, P. M. Biochemistry 1991, 30, 1227-
237.
36) Sage, J. T.; Li, P. S.; Champion, P. M. Biochemistry 1991, 30, 1237-
247.
37) Franzen, S.; Bailey, J.; Dyer, R. B.; Woodruff, W. H.; Hu, R. B.; Thomas,
M. R.; Boxer, S. G. Biochemistry 2001, 40, 5299-5305.
38) Franzen, S.; Peterson, E. S.; Brown, D.; Friedman, J. M.; Thomas, M. R.;
Boxer, S. G. Eur. J. Biochem. 2002, 269, 4879-4886.
2
3
1
1
J. AM. CHEM. SOC.
9
VOL. 127, NO. 16, 2005 5855